Riccardo De Giorgi, Clinical Lecturer at the University of Oxfords Department of Psychiatry and NIHR BRC: Oxford Health researcher said: Whether GLP-1RAs can be useful for the treatment of major neurocognitive disorders, such as dementia, is a highly debated area
The majority of these events were rated as mild to moderate in severity, and most resolved without requiring treatment discontinuation
Most GI events were classified as mild to moderate and occurred during the dose-escalation phase, consistent with the pattern seen across the GLP-1 receptor agonist class [4]
Studies have found GLP-1 receptors in the kidney itself.3 The protective effects include: reducing inflammation in kidney tissue, lowering blood pressure (by about 5-7 mmHg), improving how kidneys filter blood, and reducing protein leakage into urine an early warning sign of kidney damage.4 THE BIGGER PICTURE: 85,000+ PATIENTS A major meta-analysis of 11 clinical trials with 85,373 patients confirmed the kidney benefits